Elanco Animal Health (NYSE:ELAN) was up 5.3% during trading on Wednesday . The stock traded as high as $30.97 and last traded at $30.84, approximately 13,167,554 shares traded hands during trading. An increase of 63% from the average daily volume of 8,087,646 shares. The stock had previously closed at $29.28.

Several equities research analysts have recently commented on ELAN shares. Gabelli reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday. Raymond James started coverage on shares of Elanco Animal Health in a research report on Thursday, January 9th. They set a “market perform” rating for the company. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Tuesday, December 24th. Bank of America raised shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $34.00 price target for the company in a research report on Thursday, December 19th. Finally, UBS Group reduced their price target on shares of Elanco Animal Health from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. Elanco Animal Health has a consensus rating of “Hold” and an average target price of $33.24.

The stock has a 50 day moving average of $28.50 and a 200-day moving average of $28.72. The company has a market capitalization of $11.42 billion, a P/E ratio of 25.42, a P/E/G ratio of 2.76 and a beta of 0.74. The company has a current ratio of 3.12, a quick ratio of 1.67 and a debt-to-equity ratio of 0.43.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. The company had revenue of $771.30 million during the quarter, compared to the consensus estimate of $765.85 million. Elanco Animal Health had a return on equity of 7.79% and a net margin of 3.04%. The firm’s revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 EPS. As a group, sell-side analysts expect that Elanco Animal Health will post 1.06 EPS for the current fiscal year.

In related news, Director John P. Bilbrey acquired 3,766 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was bought at an average cost of $26.58 per share, for a total transaction of $100,100.28. Following the purchase, the director now owns 2,783 shares in the company, valued at approximately $73,972.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.04% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ELAN. Winthrop Partners WNY LLC bought a new position in Elanco Animal Health in the 3rd quarter worth approximately $25,000. Institutional & Family Asset Management LLC bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at approximately $28,000. San Francisco Sentry Investment Group CA boosted its position in shares of Elanco Animal Health by 196.7% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,157 shares of the company’s stock valued at $31,000 after acquiring an additional 767 shares during the last quarter. Toth Financial Advisory Corp bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at approximately $33,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at approximately $46,000. Institutional investors and hedge funds own 98.58% of the company’s stock.

Elanco Animal Health Company Profile (NYSE:ELAN)

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Article: Debt-To-Equity Ratio

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.